TCGA-91-6848-01A-11R-1949-07
— · cohortA1
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- cohortA1
- subtype
- cohortA1
- age_years
- 59
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- E2F_TARGETS+0.530
- MYC_TARGETS_V2+0.520
- G2M_CHECKPOINT+0.510
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.490
- MYC_TARGETS_V1+0.460
- MITOTIC_SPINDLE+0.450
- ALLOGRAFT_REJECTION+0.440
- UNFOLDED_PROTEIN_RESPONSE+0.420
- INFLAMMATORY_RESPONSE+0.360
- IL6_JAK_STAT3_SIGNALING+0.350
Top 10 suppressed
- ESTROGEN_RESPONSE_LATE-0.360
- KRAS_SIGNALING_DN-0.360
- FATTY_ACID_METABOLISM-0.340
- BILE_ACID_METABOLISM-0.310
- CHOLESTEROL_HOMEOSTASIS-0.310
- ESTROGEN_RESPONSE_EARLY-0.280
- PEROXISOME-0.210
- INTERFERON_ALPHA_RESPONSE-0.190
- P53_PATHWAY-0.190
- PANCREAS_BETA_CELLS-0.180
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | 4d36189e-fe88-4cfb-970b-a51b8e9e0783 | — | — | 0.837 |
| 2 | SRR934813 | — | — | 0.831 |
| 3 | SRR934852 | — | — | 0.829 |
| 4 | X63da1fd8.ca5b.494f.8625.4daf5f898f53 | — | cohortA1 | 0.822 |
| 5 | TCGA-DK-A3WX-01A-22R-A22U-07 | — | — | 0.817 |
| 6 | TCGA-BT-A3PJ-01A-21R-A220-07 | — | — | 0.808 |
| 7 | TCGA-85-7699-01A-11R-2125-07 | — | cohortSQ1 | 0.806 |
| 8 | SRR8518233 | — | D | 0.803 |
| 9 | ERR2208969 | — | — | 0.803 |
| 10 | TCGA-ZF-AA54-01A-11R-A39I-07 | — | — | 0.800 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 29 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| E2F_TARGETS | 0.530 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.520 | Idelalisib | — uncovered |
| G2M_CHECKPOINT | 0.510 | Inavolisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.490 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.460 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.450 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.440 | Idelalisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.420 | Idelalisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.360 | Idelalisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.350 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.320 | Inavolisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.320 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.290 | Inavolisib | — uncovered |
| KRAS_SIGNALING_UP | 0.280 | Inavolisib | — uncovered |
| COMPLEMENT | 0.250 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.220 | Idelalisib | — uncovered |
| DNA_REPAIR | 0.210 | Idelalisib | — uncovered |
| TGF_BETA_SIGNALING | 0.210 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.180 | Remibrutinib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.170 | Idelalisib | — uncovered |